Case Study: Pharma

Learn how to leverage federated and sensitive data at scale and how you can collaborate with your partners to advance and evolve the practice of life sciences.

In this case study you will learn:


How two pharma companies use protein-ligand interaction data and AI models to predict target binding of novel compounds


How a pharma company fueld their drug discovery activities by leveraging molecule data from their suppliers


How an AI-focussed health tech company developed AI models to improve decision-making processes for cancer treatments

Recommended for you

White Paper

Privacy-preserving Data Ecosystems in Support of Drug Discovery

In recent years, Deep Learning has gained considerable traction in many fields, but none more so than in the realm of drug discovery. Applications range from generating de novo hit-like molecules, predicting drug-disease associations and activity, toxicology estimation, to the analysis of medical images.

White Paper

Privacy-preserving Data Science on QSAR models

This case study shows the effectiveness of Apheris’ platform and services for data science on data that is not directly accessible and distributed. Federated learning decentralizes learning algorithms to access multiple data sets, maintaining privacy. Without pooling sensitive data, new insights can be uncovered securely.


The Three Adoption Stages of Privacy-enhancing Technologies (And Why We Are Stuck on Level Two)

PETs are massively changing how we operate, and how we have to think about the data and AI landscape. Introducing such a game-changer into large enterprises has to be done with the highest precision, and a lot of foresight.